Adams J - Search Results

1

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM. Hamilton AL, et al. Among authors: adams j. J Clin Oncol. 2005 Sep 1;23(25):6107-16. doi: 10.1200/JCO.2005.01.136. J Clin Oncol. 2005. PMID: 16135477 Clinical Trial.

2

Proteasome inhibition: a new strategy in cancer treatment.

Adams J, Palombella VJ, Elliott PJ. Adams J, et al. Invest New Drugs. 2000 May;18(2):109-21. doi: 10.1023/a:1006321828515. Invest New Drugs. 2000. PMID: 10857991 Review.

3

Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Frankel A, et al. Among authors: adams j. Clin Cancer Res. 2000 Sep;6(9):3719-28. Clin Cancer Res. 2000. PMID: 10999766

4

Proteasome inhibition measurements: clinical application.

Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Lightcap ES, et al. Among authors: adams j. Clin Chem. 2000 May;46(5):673-83. Clin Chem. 2000. PMID: 10794750

5

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C. Sunwoo JB, et al. Among authors: adams j. Clin Cancer Res. 2001 May;7(5):1419-28. Clin Cancer Res. 2001. PMID: 11350913

6

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, Cusack JC Jr. Russo SM, et al. Among authors: adams j. Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93. doi: 10.1016/s0360-3016(01)01446-8. Int J Radiat Oncol Biol Phys. 2001. PMID: 11316563

7

New agents in cancer clinical trials.

Adams J, Elliott PJ. Adams J, et al. Oncogene. 2000 Dec 27;19(56):6687-92. doi: 10.1038/sj.onc.1204088. Oncogene. 2000. PMID: 11426656 Review. No abstract available.

8

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr. Cusack JC Jr, et al. Among authors: adams j. Cancer Res. 2001 May 1;61(9):3535-40. Cancer Res. 2001. PMID: 11325813

9

Proteasome inhibition: A novel mechanism to combat asthma.

Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Elliott PJ, et al. Among authors: adams j. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):294-300. doi: 10.1016/s0091-6749(99)70369-6. J Allergy Clin Immunol. 1999. PMID: 10452747

10

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.

Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP. Shah SA, et al. Among authors: adams j. J Cell Biochem. 2001 Apr 2-27;82(1):110-22. doi: 10.1002/jcb.1150. J Cell Biochem. 2001. PMID: 11400168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,999 results

Search Page

Filters